Estradiol News and Research

RSS

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.

Red wine could play a role in lowering risk of breast cancer

Aromatase inhibitors (AIs) prevent the conversion of androgens to estrogens, and could play a role in the development of breast cancer. This study of 36 pre-menopausal women consisted of a cross-over intervention trial to determine if there were differences between red wine and white wine in their effects on AIs.

20 Jan 2012

Watson introduces new oral contraceptive, Vestura

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.

18 Jan 2012

Woman's ovarian cycle plays an important role in her susceptibility to infection

A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection.

4 Jan 2012

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated results of a Phase III study of Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing.

8 Dec 2011

Watson introduces Amethia Lo and ethinyl estradiol tablets

Watson Pharmaceuticals, Inc. today announced that under a settlement with Teva Women's Health, Watson has launched Amethia Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE.

8 Dec 2011

Mylan confirms generic Generess Fe patent challenge

Mylan Inc. today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

2 Dec 2011

FDA approves Watson's ANDA for generic Yaz oral contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz oral contraceptive product.

29 Nov 2011

BioSante listed on NASDAQ Biotechnology Index

BioSante Pharmaceuticals, Inc. today announced that it has been added to the NASDAQ Biotechnology Index, effective prior to the stock market open today, November 21, 2011.

21 Nov 2011

Mylan settles Vivelle-Dot patent litigation lawsuit with Novartis

Mylan Inc. today announced that it has settled a patent litigation lawsuit with Novartis Pharmaceuticals Corporation related to Vivelle-Dot® (Estradiol Transdermal System USP, Twice-Weekly, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day and 0.075 mg/day and 0.1 mg/day).

21 Nov 2011

Additional results from BioSante's LibiGel pK study on HSDD

BioSante Pharmaceuticals, Inc., today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Top line data from this study were announced on September 12, 2011.

16 Nov 2011

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Famy Care, Mylan resolve Femcon Fe Chewable Tablets litigation with Warner Chilcott

Mylan Inc. today announced that it, along with Famy Care Ltd., has entered into a settlement agreement with Warner Chilcott resolving litigation related to Femcon Fe Chewable Tablets, known generically as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets USP (Chewable), 75 mg (28-Day Regimen).

19 Oct 2011

NextBio predicts mechanisms underlying drug toxicity and identifies new cancer biomarker

New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation.

15 Oct 2011

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

11 Oct 2011

Estradiol plays an important role in several metabolic diseases

Hormone researchers at the University of Houston (UH) have their sights set on providing long-term treatment options for diabetes, obesity and cardiovascular diseases by better understanding estradiol, the most potent naturally occurring estrogen.

30 Sep 2011

S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women

A soy germ-based nutritional supplement containing Natural S-equol significantly improved the appearance of crow's feet skin wrinkles of the outer corner of the eyes in Japanese menopausal women, suggesting that supplements containing Natural S-equol have potential to slow skin aging, according to data from a controlled pilot study simultaneously published online in the peer-review journal Menopause and presented in a poster session at the North American Menopause Society annual meeting.

22 Sep 2011

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.

14 Sep 2011